- New ways to treat bladder cancer improve survival and shake up the standard of care, new studies show CNN
- Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO BioSpace
- Seagen, Astellas post Phase 3 win for bladder cancer therapy (NASDAQ:SGEN) Seeking Alpha
- Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial Carcinoma OncLive
- Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer BioSpace
- View Full Coverage on Google News
Read original article here